Profile data is unavailable for this security.
About the company
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
- Revenue in USD (TTM)0.00
- Net income in USD-65.02m
- Incorporated2015
- Employees41.00
- LocationQ32 Bio Inc830 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (781) 999-0232
- Fax+1 (302) 655-5049
- Websitehttps://www.q32bio.com/
More ▼
Mergers & acquisitions
| Acquired company | QTTB:NMQ since announced | Transaction value |
|---|---|---|
| Q32 Bio Inc | 197.79% | -- |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. | 35.19m | -86.45m | 535.03m | 116.00 | -- | -- | -- | 15.21 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 538.01m | 59.00 | -- | 3.53 | -- | 1,315.42 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Neurogene Inc | 925.00k | -55.44m | 540.01m | 91.00 | -- | 3.48 | -- | 583.80 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Eliem Therapeutics Inc | 0.00 | -64.20m | 555.26m | 9.00 | -- | 2.49 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Entrada Therapeutics Inc | 239.40m | 104.44m | 557.99m | 168.00 | 5.07 | 1.30 | 5.17 | 2.33 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 558.91m | 106.00 | -- | 1.90 | -- | 25.74 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Celcuity Inc | 0.00 | -82.59m | 562.49m | 55.00 | -- | 3.18 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 568.43m | 180.00 | -- | 2.20 | -- | 3.47 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 568.86m | 41.00 | -- | 16.88 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 579.49m | 44.00 | -- | 1.71 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Alector Inc | 55.28m | -160.66m | 597.55m | 245.00 | -- | 3.97 | -- | 10.81 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 601.69m | 28.00 | -- | 2.07 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -32.74m | 605.37m | 42.00 | -- | 2.34 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -72.31m | 607.13m | 6.00 | -- | 2.96 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Q32 Bio Inc's reporting currency: US Dollar USD
13.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Jun 2024 | 313.94k | 2.60% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 308.77k | 2.56% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 179.44k | 1.49% |
| Harvard Management Co., Inc.as of 30 Jun 2024 | 162.97k | 1.35% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 156.50k | 1.30% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 134.64k | 1.12% |
| Ikarian Capital LLCas of 30 Jun 2024 | 109.09k | 0.91% |
| Geode Capital Management LLCas of 30 Jun 2024 | 107.65k | 0.89% |
| Platinum Investment Management Ltd.as of 30 Jun 2024 | 89.46k | 0.74% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 81.30k | 0.67% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
